Big pharma has made serious AI bets. The real question now is where those bets are changing outcomes.

On November 5, the Nasdaq-100 fell 6.4% in a single day. Nvidia fell about 9%, and about $2.5 trillion in Nasdaq-100 market value disappeared. Reuters linked the selloff to fears that the Democratic sweep in the US midterms could slow the build-out of AI data centres [1].
It was not a verdict on AI itself. But it was a reminder that markets are starting to ask harder questions about the returns on massive AI investment. Pharma should be asking similar questions.
Over the last few years, AI has become part of almost every pharma conversation: faster drug discovery, smarter clinical trials, quicker regulatory reviews and sharper commercial decisions. The selloff raises a simple question for the industry: how much of this is delivering real value, and how much still rests on future promises?
The answer depends on where you look. Some uses of AI are already part of everyday work. Some have promising but narrow evidence. And some still have to prove they can change the economics of drug development.
In October 2025, Eli Lilly announced it was building an AI supercomputer with more than 1,000 Nvidia GPUs [2]. In January, the two companies said they plan to invest up to $1 billion over five years in a joint AI lab [3].
Novo Nordisk has signed three major AI partnerships this year, with OpenAI, Amazon Web Services and Anthropic, without disclosing the financial terms [4][5][6].
On paper, that looks like the same kind of AI enthusiasm investors just punished. The numbers tell a calmer story. Lilly spent $13.3 billion on R&D in 2025 [7]. The lab is a joint commitment that covers people, infrastructure and compute, so it is not a like-for-like comparison. But even if Lilly carried the full amount alone, it would come to about $200 million a year, roughly 1.5% of its research budget. Novo’s three deals also cover different needs: AI across the whole business with OpenAI, cloud and drug discovery tools with AWS, and drug discovery work with Anthropic. That points to a company exploring AI across many parts of its operations, not relying on a single use case.
Still, a big investment or a long list of partnerships proves nothing on its own. What matters is whether these bets produce better drug candidates, faster trials or more reliable supply. The sharper bubble risk sits with smaller AI-first biotechs whose valuations rest on platforms that have yet to produce an approved drug. They run on investor patience, and investor patience is exactly what a selloff tests.
The clearest value today is rarely in discovering the next blockbuster. It is in helping teams work through large volumes of information and repetitive tasks.
A more concrete example comes from the FDA itself. In December 2025, it qualified AIM-NASH, an AI tool that helps pathologists score liver biopsies in MASH trials, as its first qualified AI drug development tool. Pathologists still review and accept or reject every score [12]. It solves one defined problem, the variation in how biopsies are scored, and that is a far stronger case than a general claim that AI makes trials faster.
One of the most closely watched tests is Insilico Medicine’s rentosertib, which started a 52-week Phase 3 trial in about 320 patients with idiopathic pulmonary fibrosis (IPF), with the first patient dosed in September 2026 [20][21]. The trial’s lead investigator has said that, even under favourable conditions, regulatory approval could still be three to four years away [21].
For commercial and forecasting teams, AI already speeds up the routine work: cleaning and matching data, refreshing models, spotting anomalies and running scenarios. But a faster analysis is a different thing from a better forecast. Forecasts rest on assumptions about patient starts, persistence, access and competition, and someone still has to understand and own those assumptions.
There is also a less obvious effect. Sometimes, the AI application that has the biggest impact on a forecast is not the one being used by the forecasting team. It is the one improving something else in the patient journey.
That means AI’s value in forecasting should be judged two ways: how much faster a team can build a forecast, and whether AI elsewhere is changing the patient behaviour the forecast is trying to predict.
For pharma leaders weighing AI budgets after the selloff, five questions help separate a project worth funding from a demo:
And one test for the whole portfolio: would this still get funded if AI stocks fell another 30%? If the answer depends on market mood, it is a bet, not a project.
The selloff is unlikely to slow AI adoption in pharma. It is more likely to change which projects get funded. The first AI wins that big pharma can report with real numbers will probably come from trial enrolment, safety processing and patient access, well before any AI-discovered drug reaches the market.
AI does not need to discover a blockbuster drug tomorrow to prove its worth. Recruiting patients faster, processing safety cases more efficiently or keeping one more prescribed patient on therapy is already meaningful progress, and it shows up in the numbers.
Prepared by PharmSight Research & Analytics for informational purposes only.